Staff directory Giulio Rosati



  • Metabolomics for personalized medicine: the input of analytical chemistry from biomarker discovery to point-of-care tests

    Castelli F.A., Rosati G., Moguet C., Fuentes C., Marrugo-Ramírez J., Lefebvre T., Volland H., Merkoçi A., Simon S., Fenaille F., Junot C. Analytical and Bioanalytical Chemistry; 2021. 10.1007/s00216-021-03586-z. IF: 4.142

    Metabolomics refers to the large-scale detection, quantification, and analysis of small molecules (metabolites) in biological media. Although metabolomics, alone or combined with other omics data, has already demonstrated its relevance for patient stratification in the frame of research projects and clinical studies, much remains to be done to move this approach to the clinical practice. This is especially true in the perspective of being applied to personalized/precision medicine, which aims at stratifying patients according to their risk of developing diseases, and tailoring medical treatments of patients according to individual characteristics in order to improve their efficacy and limit their toxicity. In this review article, we discuss the main challenges linked to analytical chemistry that need to be addressed to foster the implementation of metabolomics in the clinics and the use of the data produced by this approach in personalized medicine. First of all, there are already well-known issues related to untargeted metabolomics workflows at the levels of data production (lack of standardization), metabolite identification (small proportion of annotated features and identified metabolites), and data processing (from automatic detection of features to multi-omic data integration) that hamper the inter-operability and reusability of metabolomics data. Furthermore, the outputs of metabolomics workflows are complex molecular signatures of few tens of metabolites, often with small abundance variations, and obtained with expensive laboratory equipment. It is thus necessary to simplify these molecular signatures so that they can be produced and used in the field. This last point, which is still poorly addressed by the metabolomics community, may be crucial in a near future with the increased availability of molecular signatures of medical relevance and the increased societal demand for participatory medicine. Graphical abstract: [Figure not available: see fulltext.]. © 2021, The Author(s).

  • The Microbiome Meets Nanotechnology: Opportunities and Challenges in Developing New Diagnostic Devices

    Fuentes-Chust C., Parolo C., Rosati G., Rivas L., Perez-Toralla K., Simon S., de Lecuona I., Junot C., Trebicka J., Merkoçi A. Advanced Materials; 33 (18, 2006104) 2021. 10.1002/adma.202006104. IF: 30.849

    Monitoring of the human microbiome is an emerging area of diagnostics for personalized medicine. Here, the potential of different nanomaterials and nanobiosensing technologies is reviewed for the development of novel diagnostic devices for the detection and measurement of microbiome-related biomarkers. Moreover, the current and future landscape of microbiome-based diagnostics is defined by exploring the advantages and disadvantages of current nanotechnology-based approaches, especially in the context of developing point-of-care (PoC) devices that would meet the international guidelines known as REASSURED (Real-time connectivity; Ease of specimen collection; Affordability; Sensitivity; Specificity; User-friendliness; Rapid & robust operation; Equipment-free; and Deliverability). Finally, the strategies of the latest international scientific consortia working in this field are analyzed, the current microbiome diagnostics market are reported and the principal ethical, legal, and societal issues related to microbiome R&D and innovation are discussed. © 2021 Wiley-VCH GmbH


  • Lateral flow assay modified with time-delay wax barriers as a sensitivity and signal enhancement strategy

    Sena-Torralba A., Ngo D.B., Parolo C., Hu L., Álvarez-Diduk R., Bergua J.F., Rosati G., Surareungchai W., Merkoçi A. Biosensors and Bioelectronics; 168 (112559) 2020. 10.1016/j.bios.2020.112559. IF: 10.257

    The ease of use, low cost and quick operation of lateral flow assays (LFA) have made them some of the most common point of care biosensors in a variety of fields. However, their generally low sensitivity has limited their use for more challenging applications, where the detection of low analytic concentrations is required. Here we propose the use of soluble wax barriers to selectively and temporarily accumulate the target and label nanoparticles on top of the test line (TL). This extended internal incubation step promotes the formation of the immune-complex, generating a 51.7-fold sensitivity enhancement, considering the limit of quantification, and up to 96% signal enhancement compared to the conventional LFA for Human IgG (H-IgG) detection. © 2020 Elsevier B.V.